Skip to content

EFZO-Fit Trial for Pulmonary Sarcoidosis

Search Clinical Trials

Trial Objectives

Researchers want to understand if an investigational medication called efzofitimod is safe, effective and tolerated by people with pulmonary sarcoidosis in the EFZO-Fit trial. The trial will also evaluate if efzofitimod can maintain lung function and allow people to lower their dose of steroids used as treatment for pulmonary sarcoidosis. Participants will receive a monthly IV infusion of a randomly assigned efzofitimod or a placebo (an inactive substance that looks the same and is administered the same as efzofitimod).

Who Can Participate

Adults who have a confirmed pulmonary sarcoidosis diagnosis for at least six months and have been receiving a prednisone treatment for at least three months, with a steady dose of prednisone for four weeks prior to enrolling in the study.

Age: 18-75 Gender: Any

Estimated Time Commitment

Monthly visits over 52 weeks

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Stephanie Leonard

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

aTyr Pharma, Inc.

Principal Investigators

Clara Restrepo

Clara Restrepo, MD


Shu-Yi Liao

Shu-Yi Liao, MD, MPH, ScD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required